Esperienza lavorativa

Ottobre 2018 - Oggi

Professore Associato presso Dipartimento di Scienze Biomediche Sperimentali e Cliniche “M. Serio” dell’Università degli Studi di Firenze (SSD MED/36) con attività clinica assistenziale presso la SOD complessa di Radioterapia della Azienda Ospedaliero-Universitaria Careggi di Firenze.

Referente formale del Gruppo Oncologico Multidisciplinare (GOM) neoplasia mammaria dell’AOUC come Oncologo Clinico/Radioterapista (da maggio 2012, incarico attualmente in corso).

Responsabile Ambulatori (Prime Visite, Rivalutazioni, e Follow Up) della SOD complessa di Radioterapia della AOUC di Firenze (da gennaio 2018, incarico attualmente in corso).

Abilitazione Scientifica Nazionale (ASN), Professore di I fascia Settore Scientifico Disciplinare (SSD) MED/36, conseguita nel 2018 (scadenza 2024).

Agosto 2011 - Settembre 2018

Dirigente Medico di 1° livello presso la SOD complessa di Radioterapia della Azienda Ospedaliero-Universitaria Careggi (AOUC) di Firenze.

Luglio 2010 – Luglio 2011

Titolare di Assegno di Ricerca dal titolo “Valutazione della predisposizione genetica alla tossicità radio indotta” (DAI Oncologia, SOD complessa di Radioterapia), afferente al Dipartimento di Fisiopatologia Clinica dell’Università degli Studi di Firenze, dal 1° luglio 2010 al 30 luglio 2011. Supervisore: Prof. Giampaolo Biti.

Istruzione e formazione

2017-2018              Master di II livello “Farmaci oncologici e radioterapia: biologia e clinica”. Università degli Studi di Brescia, Dipartimento di Specialità Medico Chirurgiche, Scienze Radiologiche e Sanità Pubblica.

2005-2009              Specializzazione in Radioterapia conseguita in data 09/11/2009 con la votazione 70/70 e lode presso la Scuola di Specializzazione in Radioterapia dell’Università degli Studi di Firenze (durata 4 anni), con il lavoro di tesi: “Carcinoma mammario in pazienti trattate per Linfoma di Hodgkin: esperienza dell’Università di Firenze”. Relatore: Prof. Giampaolo Biti.

2008-2009              Fellowship presso l’Unità di Radioterapia Oncologica del Royal Marsden Hospital, London (UK). Supervisore: Prof. Michael Brada.

2005-2006              Titolare da ottobre 2005 a marzo 2006 di un incarico professionale presso il Dipartimento di Fisiopatologia Clinica dell’Università degli Studi di Firenze dal titolo “Risk-assessment in Radiotherapy”. Progetto europeo no. LSHC-CT-2004-503564 del VI programma quadro MAESTRO (Methods and Advanced Equipment for Simulation and Treatment in Radio Oncology).             

1999-2005              Laurea in Medicina e Chirurgia conseguita in sei anni presso la Facoltà di Medicina e Chirurgia dell’Università degli Studi di Firenze il 25 luglio 2005 con il lavoro di tesi: “Carcinoma prostatico localizzato trattato con radioterapia ad intensità modulata (IMRT)”. Relatore: Prof. Giampaolo Biti. Laurea conseguita con voto 110/110 e lode.

1994-1999              Diploma di maturità scientifica conseguito in cinque anni presso il “Liceo Scientifico Statale N. Rodolico”, Firenze, a pieni voti (100/100) nel 1999.

Madrelingua

Italiano

Inglese

• Capacità di lettura

Eccellente

• Capacità di scrittura

Eccellente

• Capacità di espressione orale

Eccellente

Spagnolo

• Capacità di lettura

Buono

• Capacità di scrittura

Buono

• Capacità di espressione orale

Buono

Produzione Scientifica

Attività scientifica, didattica e servizi

Autore di oltre 120 pubblicazioni su riviste internazionali, dotate di Impact Factor e soggette a valutazione anonima ed indipendente da pari esperti del settore. Consultabili su https://www.ncbi.nlm.nih.gov/pubmed/?term=meattini+i.

Organizzazione e partecipazione come relatore a convegni di carattere scientifico nazionali ed internazionali

• Comitato Organizzatore Locale del XVII Congresso Nazionale dell'Associazione Italiana Radioterapia Oncologica (AIRO) 2007, Firenze.
• Relazione ad invito. XXII Congresso Nazionale AIRO. Roma. Relazione ad invito dal titolo “La radioterapia dopo terapia sistemica neoadiuvante: irradiazione delle catene linfonodali? cons“. 17-20/11/2012.
• Relazione. Workshop “Il carcinoma avanzato della mammella: evidenze e prospettive future”. Montecatini Terme. 24/05/2013.
• Relazione ad invito. 17th ECCO - 38th ESMO - 32nd ESTRO. European Cancer Congress: Reinforcing Multidisciplinarity. Amsterdam, The Netherlands. Invited speaker in the Roundtable Session on "How to Improve Career Opportunities for Young Oncologists Accross Europe". 27/09/2013-01/10/2013.
• Relazione ad invito. XXIII Congresso Nazionale AIRO. Taormina. “Tossicità nelle associazioni con le terapie sistemiche“. 26-29/10/2013.
• Relazione selezionata. ESTRO 33, Vienna, Austria from 04-08 April 2014. Selected oral communication in the session Clinical 9: Breast cancer. Toxicity of APBI using IMRT versus whole breast irradiation: 3-year follow-up of a Phase III randomized trial with first (presenting author) I. Meattini. 4-8/04/2014.
• Relazione. Workshop “La malattia aggressiva e la malattia indolente nel tumore alla mammella in stadio avanzato”. Pontedera. 19/06/2014.
• Relazione. Workshop “La terapia del Carcinoma mammario Metastatico: ruolo delle antracicline”, Pisa. 08/10/2014.
• Relazione. Workshop "Costruire il miglior percorso terapeutico per la paziente aBC HR+/HER2-", Montecatini. 31/10/2014.
• Relazione ad invito. XXIV Congresso Nazionale AIRO. Padova. “Grandangolo in Radioterapia Oncologica 2014”. 9-11/11/2014.
• Relazione ad invito. “Consensus sulla nuova indicazione in seconda linea di eribulina”, Reggio Emilia. 03/03/2015.
• Relazione selezionata. 3rd ESTRO Forum, Barcelona, Spain. Presentation as a poster discussion in the session Clinical. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial with first (presenting author) I. Meattini. 24-28/04/2015.
• Relatore. Consensus Conference: Dalla pratica del “follow up” alla cultura del “survivorship care”, organizzata da Associazione Italiana Oncologia Medica (AIOM). Roma, 10-11/09/2015.
• Relazione ad invito. XXV Congresso Nazionale AIRO. Rimini. Simposio “Ricostruzione mammaria ed implicazioni radioterapiche”. 7-10/11/2015.
• Relazione ad invito. V AIRO ZOOM Journal Club 2015, Bologna. 19/02/2016.
• Relazione. Workshop “Determinazione di HER2” le metodiche di amplificazione. AOUC Firenze. 26/02/2016.
• Relazione. Workshop “La Breast Unit come modello assistenziale per la medicina di genere nell’AOU Careggi”, AOUC Firenze. 08/03/2016.
• Relazione ad invito. “Carcinoma mammario HER2 positivo: Highlights e prospettive”. AOU Careggi Firenze. 13/04/2016.
• Relazione. Workshop “We Breast”. Trattamento del carcinoma mammario metastatico HR+/HER2–nella paziente in post-menopausa: dalla letteratura alla pratica clinica. Chemioterapia e ormonoterapia. Prato. 14/06/2016.
• Relazione ad invito. Advisry Board: “Il trattamento delle pazienti con carcinoma della mammella metastatico ER+ HER2- con Everolimus più Exemestane: condivisione degli aspetti clinici e pratici per ottimizzare il trattamento e la gestione delle pazienti”. Antignano (Livorno). 27/06/2016.
• Relazione ad invito. Forum della sostenibilità e opportunità nel settore della salute. Tavola rotonda “Le nuove frontiere in oncologia”. Stazione Leopolda, Firenze. 23/09/2016.
• Relazione. Workshop monografico "Il governo dell'innovazione farmaceutica: modelli di gestione sostenibile dei farmaci oncologici innovativi ad alto costo". Istituto Toscano Tumori, Firenze. 27/09/2016.
• Commissione Scientifica dei XXVII-XXIX Congressi Nazionali dell'Associazione Italiana di Radioterapia Oncologica ed Oncologia Clinica (AIRO). Rimini, 2017-19.
• Relazione ad invito. XXVI Congresso Nazionale AIRO. Simposio “Farmaci innovativi nel carcinoma mammario”. Rimini. 30/09/2016 – 02/10/2016.
• Relazione ad invito. Convegno “La terapia primaria del carcinoma mammario”. I martedì oncologici di AIOM Toscana. Pisa. 04/10/2016.
• Relazione ad invito. Seminario di diagnostica senologica con presentazione interattiva di casistica ragionata. “Riprese di malattia: diagnosi e significato biologico. Utilità e limiti del follow up”. Firenze. 17-20/10/2016.
• Relazione ad invito. Corso itinerante AIRO “Consensus per l’irradiazione delle stazioni linfonodali mammarie”, Ospedale dell’Angelo di Venezia Mestre. 21/10/2016.
• Relazione ad invito. Brescia Meetings in Radiation Oncology. “International Research projects in cardio-oncology: focus on breast cancer”. Brescia. 17-18/11/2016.
• Relazione selezionata. ECCO 2017. Amsterdam. Proffered Paper Session: "Breast Cancer". Oral Presentation in a Proffered Paper Session. "Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: Impact of age and scores trend over time". 29/01/2017.
• Relazione ad invito. “Advanced Breast Cancer HR+: HER2- versus HER2+. Open questions. BreastINg Work: aBC HR+/HER2- un panorama in evoluzione”. Camogli, 31/03/2017 – 01/04/2017.
• Relazione ad invito. Lecture on External beam partial breast irradiation: changing patient selection based on current evidence in the symposium on Selection of patients and radiotherapy technique for APBI in the light of new phase III trial data. ESTRO 36, Vienna. 5-9/05/2017.
• Relazione ad invito. Gestione della paziente con carcinoma metastatico della mammella. Pisa, 11 maggio 2017.
• Relazione ad invito. Consensus conference “Il Carcinoma in situ della mammella”. Catania. 18-20/05/2017.
• Relazione ad invito. “Corso di Aggiornamento in Cardio-Oncologia”. Pietrasanta. 15/09/2017.
• Relazione ad invito. “Carcinoma mammario metastatico con recettori ormonali positivi. Quale entità clinica?”. Bergamo. 22-23/09/2017.
• Relazione ad invito. Selezionato da European Society for Radiation Oncology (ESTRO) e European Organisation for the Research and Treatment of Cancer (EORTC) come Representative Speaker al Meeting Annuale di Korean Society for Radiation Oncology (KOSRO). Seoul (Korea). 13/10/2017.
• Comitato Esecutivo della IX edizione del Congresso Attualità in Senologia (AIS). Firenze. 8-10/11/2017.
• Relatore ad invito. Convegno “Highlights in Radioterapia. Quali novità dai Congressi Internazionali 2017”. Centro Studi Area Radiologica “ll Cardello”. Roma. 25/01/2018.
• Comitato Esecutivo ed Expert Board. "2° Think Tank meeting on research challenges in breast cancer”, endorsed by ESTRO. Assisi 1-3/03/2018.
• Organizzatore Locale dello Spring Meeting del Gruppo di Radioterapia Oncologica (ROG) dell'Organizzazione Europea per la Ricerca e la Cura del Cancro (EORTC). Firenze- 11-13/03/2018.
• Relazione ad invito. Panel of Experts. 11th European Breast Cancer Conference (EBCC). Multidisciplinary Team in the Real-World session on "Young HER2 Negative Patients with Breast Cancer". Barcelona (Spain). 21-23/03/2018.
• Relazione selezionata. Congresso ESTRO 37, Comunicazione orale selezionata "DCIS treated with breast conservative surgery and radiotherapy: a national multicentre experience". Barcelona (Spain). 20-24/04/2018.
• Relazione ad invito. Congresso “I se ed i ma del trattamento del carcinoma mammario metastatico ER+/HER2-“. Ferrara, 11-12 maggio 2018.
• Relazione ad invito. Brescia Meetings in Radiation Oncology “Immunity, drugs, radiation: from biology to comtemporary clinical oncology”. Brescia, 20-21 settembre 2018.
• Responsabile Scientifico. Corso ECM “Help Desk in aBC. Share the clinical experience”. Firenze, 5 ottobre 2018.
• Expert meeting. Breast Cancer Expert Meeting. Pisa, 13 novembre 2018.
• Relazione ad invito. Meeting Annuale dell’Associazione di Senologi Oncologi Svedesi, Brostonkologisk Forening (BOF). Hesselby Slott, Vallingby, Stoccolma (Svezia). 23-25/01/2019.
• Panel of Experts. Breast Surgery Toolbox – Hirslanden Klinik St. Anna Brustzentrum (ESTRO representative). “A consensus and toolbox to improve breast conservation rates and to guide axillary management after preoperative systemic therapy (PST)”. Lucerna (Svizzera). 8 febbraio 2019.
• Relazione ad invito. Convegno “Focus sulla chirurgia oncologica e riostruttiva della mammella”. Pisa, 11-12 Aprile 2019.
• Relazione ad invito. Congresso annuale ESTRO 38. Milano, 27-30 Aprile 2019.
• Comitato Esecutivo della XI edizione del Congresso annuale AIS. Firenze, 2019.

Direzione, organizzazione e partecipazione alle attività di gruppi di ricerca e collaborazioni a livello nazionale ed internazionale

• Consigliere della Sezione Inter-regionale Tosco-Umbra dell’Associazione Italiana Radioterapia Oncologica (GTUOR). Biennio 2013-2015.
• Vice-coordinatore del Gruppo di lavoro di Patologia Mammaria dell'Associazione Italiana di Radioterapia Oncologica ed Oncologia Clinica (AIRO). Biennio 2014-2016.
• Partecipazione alle attività del Gruppo di Radioterapia Oncologica (ROG) e del Gruppo di Neoplasia Mammaria (BCG) dell'Organizzazione Europea per la Ricerca e il Trattamento del Cancro (EORTC). 2014-ad oggi.
• Vice-coordinatore del Gruppo di lavoro di Patologia Mammaria (BWP) del gruppo di Radioterapia Oncologica (ROG) dell'Organizzazione Europea per la Ricerca ed il Trattamento del Cancro (EORTC). Triennio 2013-2018.
• Selezionato per il programma promosso da Organizzazione Europea sulla Ricerca e il Trattamento del Cancro (EORTC): Early Career Investigator EORTC Program. Programma di leadership a frequenza obbligatoria promosso per il biennio 2017-2019.
• European Organisation for Research and Treatment of Cancer (EORTC) - Radiation Oncology Group (ROG)-Disease Oriented Groups Junior Representative (jRDR) for Breast Cancer. Marzo 2018-ad oggi.
• Socio Fondatore e Presidente del Gruppo di Studio multicentrico nazionale/internazionale denominato "Clinical Oncology Breast Cancer Group - Gruppo di Studio di Oncologia Clinica del Tumore Mammario" (COBCG). Marzo 2018-ad oggi.
• Membro effettivo del Collegio Italiano dei Senologi. dal 20/09/2016-ad oggi.
• Membro effettivo dell’Associane Italiana di Radioterapia Oncologica ed Oncologia Clinica (AIRO) dal 2006.
• Membro effettivo dell’Associazione Italiana di Radio-Biologia (AIRB).
• Membro effettivo di European SocieTy for Radiation Oncology (ESTRO) dal 2012.
• Membro effettivo di European Organisation for Research and Treatment of Cancer (EORTC) dal 2014.

Responsabilità e coordinamento di studi e ricerche scientifiche

• Co-Principal Investigator. APBI-IMRT-Florence (NCT02104895) phase III trial. Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation. Istituzione: Università degli Studi di Firenze.
• Sub-Investigator. PERTAIN Trial (Hoffmann-La Roche. A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer. NCT01491737.
• Sub-Investigtor. SAFE HER trial (Hoffmann-La Roche). A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer). NCT01566721.
• Sub-Investigator. BELLE3 trial (Novartis). Studio randomizzato, in doppio cieco, controllato versus placebo, di Fase III, con BKM120 in associazione a fulvestrant in pazienti in post-menopausa con carcinoma mammario positivo per i recettori ormonali HER2-negativo trattato con inibitori dell’aromatasi, localmente avanzato o metastatico che ha presentato progressione durante o dopo terapia con un regime contenente un inibitore di mTOR.
• Sub-Investigator. SAFE phase III trial (NCT02236806). Role of ACE Inhibitors and Beta Blockers as Cardiotoxicity Prevention in Breast Cancer Patients Treated With (Neo)Adjuvant Anthracyclines and/or Trastuzumab: a Four Arm, Placebo Control, Randomized Trial. Istituzione: Università degli Studi di Firenze.
• Sub-Investigator. GIM13 AMBRA (Consorzio Oncotech). Studio Osservazionale Longitudinale di Coorte sulle scelte terapeutiche del carcinoma mammario metastatico HER2-negativo nella pratica clinica Italiana.
• Sub-Investigator. GIM10 CONSENT (IRCCS AOU San Martino-IST). Studio clinico di fase III di confronto tra la somministrazione concomitante e quella sequenziale della CT e degli AI come trattamento adiuvante delle pazienti in postmenopausa con carcinoma mammario operato ormonosensibile.
• Sub-Investigator. SANDPIPER Trial (Hoffmann-La Roche). SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy. NCT02340221.
• Sub-Investigator. BONADIUV phase II trial (NCT02616744). A Single--blind, Randomized, Placebo--controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial. Istituzione: Università degli Studi di Firenze.
• Sub-Investigator. GIM16 FEVEX (Consorzio Oncotech). Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopausal women with hormone receptor positive (HR+) ad human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC) previously treated with non steroidal aromatase inhibitors (NSAI): a multicentre, phase III trial.
• Sub-Investigator. SINODAR ONE trial (Fondazione Humanitas per la Ricerca – Rozzano, Milano). Carcinoma mammario T1-T2: confronto fra asportazione e conservazione dei linfonodi ascellari in presenza di metastasi al linfonodo sentinella.
• Sub-Investigator. PAINTER trial (Oncologia Medica dell'Ospedale Fatebenefratelli).PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment. NCT02864030.
• Principal Investigator. EORTC-1625 QoL-ROG-ETF-BCG phase III trial (EUROPA trial). Partial Breast Irradiation versus Endocrine Therapy for women age ≥70 years with Luminal-A early stage breast cancer: a randomized phase III trial comparing Quality of Life by Patient Reported Outcome Measures. Istituzione: Organizzazione Europea per la Ricerca e il Trattamento del Cancro (EORTC).
• Co-Investigator. Studio LUCY: Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations. Codice Eudract: 2017-001054-34.
• Co-Investigator. A European Disease Registry Study To Prospectively Observe Treatment Patterns And Outcomes In Patients With Her2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer (F. Hoffmann-La Roche Ltd). Protocol Number MO39146.
• Co-Investigator. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Efficacy And Safety Of Atezolizumab In Combination With Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer” (F. Hoffmann-La Roche Ltd). Protocol Number MO39193. Eudract Number 2016-005119-42.
• Co-Investigator. A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study Of Tezolizumab (Anti-PD-L1 antibody) In Combination With Paclitaxel compared With Placebo With Paclitaxel For Patients With Previously Untreated Inoperable Locally Advanced Or Metastatic Triple Negative Breast Cancer (F. Hoffmann-La Roche Ltd). Protocol Number MO39196 Eudract Number 2016-004024-29.
• Co-Investigator. Palbociclib Collaborative Adjuvant Study: A Randomized Phase Iii Trial Of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone For Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (Pallas). Alliance Foundation Trials, Llc. Clinicaltrials.Gov Identifier: Nct02513394.
• Co-Investigator. Non-Interventional Study To Characterize The Real World Treatment Patterns And Outcomes Of Women With ER+, HER2- Advanced Or Metastatic Breast Cancer In Italy (Pfizer). Protocol Number A5481031.
• Co-Investigator. Studio Compleement-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease. Codice Eudract: 2016-003467-19.

Responsabilità scientifica per progetti di ricerca internazionali e nazionali, ammessi al finanziamento sulla base di bandi competitivi che prevedano la revisione tra pari

• Incarico professionale presso il Dipartimento di Fisiopatologia Clinica dell’Università degli Studi di Firenze dal titolo “Risk-assessment in Radiotherapy”. Progetto europeo no. LSHC-CT-2004-503564 - VI programma quadro MAESTRO (Methods and Advanced Equipment for Simulation and Treatment in Radio Oncology). 01/10/2005 – 01/03/2006.

• Titolare di Assegno di Ricerca dal titolo “Valutazione della predisposizione genetica alla tossicità radio indotta” (DAI Oncologia, SODC Radioterapia) del Dipartimento di Fisiopatologia Clinica dell’Università degli Studi di Firenze. Regione Toscana (Bando 2009 Ricerca Regionale in Materia di Salute). 01/07/2010 – 30/07/2011.

Editorial Board

• Cancer and Clinical Oncology (ISSN: 1927-4858, Print; ISSN: 1927-4866, Online)
• Case Reports in Pathology (ISSN: 2090-6781)
• Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803)

Peer-Reviewer per Riviste Scientifiche

• Cancer and Clinical Oncology (ISSN: 1927-4858, Print; ISSN: 1927-4866, Online).
• Case report in Pathology (ISSN: 2090-6781).
• BMC Cancer (ISSN: 1471-2407).
• Onkologie (ISSN: 1423-0240).
• La radiologia medica (ISSN: 1826-6983).
• Tumor Biology (Tumor Biology Tumor Markers, Tumor Targeting and Translational Cancer Research; ISSN: 1010-4283).
• Clinical Breast Cancer (ISSN: 1526-8209).
• Urologic Oncology (ISSN: 1078-1439).
• The Breast (ISSN: 0960-9776).
• Future Oncology (ISSN 1479-6694).
• Radiotherapy and Oncology (ISSN 0167-8140)

Formale attribuzione di incarichi di insegnamento o di ricerca (fellowship) presso qualificati atenei e istituti di ricerca

• Fellowship Unità di Radioterapia Oncologica - Radiation Oncology Unit, Royal Marsden Hospital, London (UK). Supervisore: Prof. Michael Brada. dal 01-10-2008 al 31-03-2009. Attività clinica presso il “Royal Marsden Hospital” (RMH), London (UK) e attività di ricerca presso The Institute of Cancer Research (ICR), London, Sutton (UK). Ambulatori presso la sede di Chelsea e di Sutton del RMH specialistici nelle neoplasie polmonari e cerebrali (responsabile prof. Michael Brada). Attività clinica ambulatoriale presso la sede di Sutton del RMH specialistica nelle neoplasie ematologiche (responsabile prof. Alan Horwich). Discussione e partecipazione a Multi-Diciplinary Team (MDT) delle neoplasie polmonari (sede RMH di Sutton) e della patologia cerebrale (sede St. George Hospital, Wimbledon, London). Partecipazione a studi sulla tossicità polmonare indotta dal trattamento radiante nel trattamento delle neoplasie polmonari, in particolare valutazione dell'impatto della tecnica Active Breathing Control (ABC) sui DVH dei pazienti e confronto con la tecnica a respiro libero. Partecipazione a raccolta ed analisi di dati su pazienti affetti da meningioma e neurinoma dell’acustico. Partecipazione a Journal Club settimanali presso la sede RMH di Sutton. Presentazione di discussione accademica sul tema “Breast Cancer after Hodgkin disease”. Partecipazione e conferimento dell'abilitazione di Good Clinical Practice (GCP) nella pratica clinica dei trials di ricerca.
• Didattica frontale e tutoraggio studenti Corso di Laurea Magistrale in Medicina e Chirurgia in attività didattiche elettive presso SOD Radioterapia AOUC Firenze.
• Didattica frontale e tutoraggio medici in formazione specialistica Scuola di Specializzazione in Radioterapia presso SOD Radioterapia AOUC Firenze.
• Co-Relatore (Relatore Prof. Lorenzo Livi) di Tesi di Laurea a studenti del Corso di Laurea Magistrale a Ciclo Unico in Medicina a Chirurgia, della Scuola di Scienze della Salute Umana dell’Università degli Studi di Firenze.
• Relatore di Tesi di Laurea a studenti del Corso di Laurea Triennale in Tecniche di radiologia medica, per immagini e radioterapia, della Scuola di Scienze della Salute Umana dell’Università degli Studi di Firenze.
• Docente del Corso avanzato sul trattamento multidisciplinare neoplasia mammaria della Società Europea di Radioterapia Oncologica (ESTRO), ESTRO Teaching Course on the Multidisciplinary Management of Breast Cancer 2015, ESTRO School of Radiotherapy Oncology.
• Docente Corso Erasmus “Basic and Translational Oncology” Università degli Studi di Firenze/Università Parigi 7. Febbraio 2018, Firenze.
• Docente Corso Erasmus “Basic and Translational Oncology” Università degli Studi di Firenze/Università Parigi 7. 25 febbraio-1 marzo 2019, Firenze.

Attività assistenziale e clinica

Principali responsabilità clinico assistenziali (SOD complessa Radioterapia Oncologica - AOU Careggi Firenze; direttore Prof. Lorenzo Livi):

• Attività ambulatoriale focalizzata alla gestione del paziente oncologico nelle fasi di inquadramento clinico, diagnostico, terapeutico e follow-up; partecipazione a GOM, terapie associate (radioterapia, chemioterapia, terapie molecolari), terapie di supporto e palliative;
• Responsabile degli ambulatori della SOD complessa Radioterapia AOUC Firenze da gennaio 2018;
• Referente formale del GOM neoplasia mammaria dell’AOU Careggi come Oncologo Clinico/Radioterapista;
• Attività presso la Sezione Degenze Ordinaria e Protetta: terapia di supporto a pazienti oncologici con malattia avanzata, terapie sistemiche (primarie, adiuvanti, palliative) come trattamento oncologico esclusivo o in associazione a trattamento radiante;
• Attività di Day-Hospital: chemioterapie e terapie molecolari in setting primario, adiuvante e metastatico di pazienti oncologici; terapia di supporto; gestione delle rivalutazioni in corso di trattamento; partecipazione a trials clinici interni, nazionali ed internazionali (con sponsor e no-profit);
• Attività presso il Reparto Applicazioni radioterapiche: gestione di inizi terapia e visite di tolleranza al trattamento radiante; conoscenza del funzionamento di acceleratori lineari per terapia, tomoterapia elicoidale, GammaKnife, CyberKnife; utilizzo di sistemi di piani di trattamento per la contornazione e la pianificazione di trattamenti standard, conformazionali, stereotassici, IMRT, VMAT (XiO, Odyssey, Pinnacle, Monaco);
• Conoscenza di sistemi di record and verify; utilizzo di sistemi PACS per la gestione delle immagini; impiego di sistemi di verifica del posizionamento del paziente (portal imaging, CT integrate nell’acceleratore lineare) e di sistemi di immobilizzazione.
• Impiego del simulatore di terapia e della TC/simulatore per centraggio e verifica di trattamenti radioterapici, TC 4-dimensionale per pianificazione del trattamento.

Autorizzo Il Trattamento Dei Dati Personali Contenuti Nel Mio Curriculum Vitae In Base All’art. 13 Del D. Lgs. 196/2003.

Firenze, 07/02/2019

work experience

2018 – present

2018 – 2029

2011 – 2018

2010 – 2011

- Associate Professor of Radiation Oncology at Department of Experimental and Clinical Biomedical Sciences “M. Serio” – University of Florence, Florence, Italy

- Consultant Radiation and Clinical Oncologist at Azienda Ospedaliero-Universitaria Careggi (AOUC) University Hospital, Florence, Italy

- Chair of the breast cancer multidisciplinary team (MDT) for Radiation Oncology (2012 – present)

- Head of Outpatient Clinics of Radiation Oncology Unit (2017 – present)

National Scientific Qualification I level, Full Professor for Radiation Oncology (Scientific Disciplinary Sector (SSD) MED/36)

Consultant Radiation and Clinical Oncologist

AOUC University Hospital, University of Florence, Florence, Italy

Radiation Oncology Unit, Oncology Department

AOUC University Hospital, University of Florence, Florence, Italy

Research Fellowship at Radiation Oncology Unit, Oncology Department

Topic “Evaluation of genetic predisposition to induced radio toxicity”. Supervisor: Prof. Giampaolo Biti

education and training

2017 – 2019

2016 – 2018

2005 – 2009

2008 – 2009

2005 – 2006

1999 – 2005

1994 – 1999

European Organisation for Research and Treatment of Cancer (EORTC)

Early Career Investigators (ECI) Leadership Program for the management of Clinical Research in Oncology

University of Brescia, Brescia, Italy

II Degree Master on “Oncologic Drugs and Radiotherapy”

Dissertation thesis “Hypofractionation in young breast cancer patients”

Supervisor: Prof. Stefano M. Magrini

University of Florence, Florence, Italy

Postgraduate Degree in Radiation Oncology. Dissertation topic “Breast cancer in patients treated for Hodgkin lymphoma: University of Florence experience”.

Supervisor: Prof. Giampaolo Biti. 70/70 cum Laude

Royal Marsden Hospital, London, UK

Fellowship at Royal Marsden Hospital, London (UK). Supervisor: Prof. Michael Brada.

University of Florence, Florence, Italy

Research fellow at Department of Clinical Physiopathology

Topic: "Risk-assessment in Radiotherapy". [European project LSHC-CT-2004-503564 of 6^th program MAESTRO (Advanced Methods and Equipment for Simulation and Treatment in Oncology Radiology)].

University of Florence, Florence, Italy

Medical Degree. Dissertation topic “Localized prostate cancer treated with intensity-modulated radiation therapy (IMRT)” Supervisor: Prof. Giampaolo Biti. 110/110 cum Laude.

High School “N. Rodolico”, Florence, Italy

Scientific High school degree. 100/100.

personal skills

Mother tongue

Italian

Foreign languages

English

UNDERSTANDING

Reading

Listening

C1

C1

SPEAKING

Spoken interaction

Spoken production

C1

C1

WRITING

C1

Spanish

UNDERSTANDING

Reading

Listening

B2

B2

SPEAKING

Spoken interaction

Spoken production

WRITING

B2

B2

B2

Scientific Publications

Scientific and Educational Activities

Author of more than 230 peer-reviewed scientific publications in international journals, available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=meattini+i

h-index: 28 (May 25, 2023)

Organization and participation as a speaker at national and international scientific conferences.

• Local Organizing Committee of the XVII National Congress of the Italian Association of Radiotherapy Oncology (AIRO) 2007, Florence, Italy.

• Invited speaker. XXII AIRO National Congress. Rome. Topic: "Radiotherapy after neoadjuvant system therapy: irradiation of the lymph node chains? cons ". 17-20/11/2012.

• Invited speaker. Workshop topic: "Advanced Breast Cancer: Evidence and Future Perspectives". Montecatini Terme, Italy. 24/05/2013.

• Invited speaker. 17th ECCO - 38th ESMO - 32nd ESTRO. European Cancer Congress: Reinforcing Multidisciplinary. Amsterdam, Netherlands.

• Invited speaker in the Roundtable Session on "How to Improve Career Opportunities for Young Oncologists Across Europe". 27/09/2013-01/10/2013.

• Invited speaker. XXIII AIRO National Congress. Taormina, Italy. "Toxicity in associations with systemic therapies". 26-29/10/2013.

• Report. ESTRO 33, Vienna, Austria. Selected oral communication in the session Clinical. Topic: “Breast cancer. Toxicity of APBI using IMRT versus whole breast irradiation: 3-year follow-up of a Phase III randomized trial with first (presenting author) I. Meattini. 4-8 / 04/2014.

• Invited speaker. Workshop topic: "Aggressive disease and indolent disease in advanced stage breast cancer". Pontedera, Italy. 06/19/2014.

• Invited speaker. Workshop topic: "Metastatic breast cancer therapy: role of anthracyclines", Pisa, Italy. 08/10/2014.

• Invited speaker. Workshop topic: "Building the best therapeutic program for the BC+ HR+/HER2- patient", Montecatini, Italy. 31/10/2014.

• Invited speaker. XXIV AIRO National Congress. Padua, Italy. "Wide Angle in Oncological Radiotherapy 2014". 9-11/11/2014.

• Invited speaker. Topic: "Consensus on the new indication in the eribulin as second line therapy ", Reggio Emilia. 03/03/2015.

• Report. 3rd ESTRO Forum, Barcelona, ​​Spain. Presentation as a poster discussion in the Clinical session. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomized trial with first (presenting author) I. Meattini. 24-28 / 04/2015.

• Consensus Conference speaker. Topic: from the practice of "follow up" to the culture of "survivorship care", organized by the Italian Association of Medical Oncology (AIOM). Rome, 10-11/09/2015.

• Invited speaker. XXV AIRO National Congress. Rimini, Italy. Symposium "Breast reconstruction and radiotherapy implications". 7-10/11/2015.

• Invited speaker. V AIRO ZOOM Journal Club 2015, Bologna, Italy. 19/02/2016.

• Invited speaker. Workshop Topic: "HER2 determination" amplification methods. AOUC Florence, Italy. 26/02/2016.

• Invited speaker. Workshop topic: "The Breast Unit as a model of care for gender medicine in the AOU Careggi", AOUC Florence, Italy. 08/03/2016.

• Invited speaker. "HER2 positive breast carcinoma: Highlights and perspectives". AOU Careggi Florence, Italy. 13/04/2016.

• Invited speaker. "We Breast". Workshop topic: “Treatment of HR +/HER2 metastatic breast cancer in postmenopausal patients: from literature to clinical practice. Chemotherapy and hormone therapy”. Prato, Italy 14/06/2016.

• Invited speaker. Advisory Board. Topic: "Treatment of patients with ER + HER2 metastatic breast cancer with Everolimus plus Exemestane: sharing of clinical and practical aspects to optimize treatment and management of patients". Antignano (Livorno), Italy. 27/06/2016.

• Invited speaker. Sustainability forum and opportunities in the health sector. Roundtable "The new frontiers in oncology". Stazione Leopolda, Florence, Italy. 23/09/2016.

• Invited speaker. Workshop Topic: "The Government of Pharmaceutical Innovation: Models of Sustainable Management of Innovative and High Cost Oncology Drugs". Istituto Toscano Tumori, Florence, Italy. 27/09/2016.

• Scientific Commission of the XXVII and XXVIII National Congress of the Italian Association of Radiotherapy Oncology (AIRO). Rimini, Italy 2017-2018.

• Invited speaker. XXVI AIRO National Congress. Symposium: "Innovative drugs in breast cancer". Rimini, Italy. 30/09/2016 - 02/10/2016.

• Invited speaker. Conference "Primary therapy in breast cancer". Oncological Tuesdays of AIOM Toscana. Pisa, Italy. 04/10/2016.

• Invited speaker. Senological diagnostics seminary with interactive presentation. Topic: "Disease recovery: diagnosis and biological meaning. Utilities and limits of follow-up ". Florence, Italy. 17-20/10/2016.

• Invited speaker. Itinerary section AIRO "Consensus for the irradiation of the mammary lymph node stations", Ospedale dell'Angelo di Venezia Mestre, Italy. 21/10/2016.

• Invited speaker. Brescia Meetings in Radiation Oncology. "International Research projects in cardio-oncology: focus on breast cancer". Brescia, Italy. 17-18 /11/2016.

• Report. ECCO 2017. Amsterdam, Netherlands. Proffered Paper Session: "Breast Cancer". Oral Presentation in a Proffered Paper Session. IMRT-Florence phase 3 trial: "Health-related quality of life analysis from the accelerated partial breast irradiation". 29/01/2017.

• Invited speaker. "Advanced Breast Cancer HR +: HER2- versus HER2 +. Open questions. BreastINg Work: aBC HR + / HER2 - an evolving panorama ". Camogli, Italy 31/03/2017 - 01/04/2017.

• Invited speaker. Topic: “Lecture on External beam partial irradiation”. ESTRO 36, Vienna, Austria. 5-9 /05/2017.

• Invited speaker. Topic: “Management of the patient with metastatic breast cancer”. Pisa, Italy 11 May 2017.

• Consensus conference. Topic: "In situ carcinoma of the breast". Catania, Italy. 18-20/05/2017.

• Invited speaker. Topic: "Update Course in Cardio-Oncology". Pietrasanta, Italy. 15/09/2017.

• Invited speaker. Topic: "Metastatic breast carcinoma with positive hormone receptors. Which clinical entity? ". Bergamo, Italy. 22-23/09/2017.

• Invited speaker. European Society for Radiation Oncology (ESTRO) and European Organization for the Research and Treatment of Cancer (EORTC). Speaker at the Annual Meeting of the Korean Society for Radiation Oncology (KOSRO). Seoul, Korea. 13/10/2017.

• Executive Committee of the IX edition of the Congress in Senology (AIS). Florence, Italy. 8-10/11/2017.

• Invited speaker. Topic: "Highlights in Radiotherapy. What news from the 2017 International Congresses”? "Il Cardello" Radiological Research Center. Rome, Italy. 25/01/2018.

• Executive Committee and Expert Board of the "2nd Think Tank meeting on research challenges in breast cancer", endorsed by ESTRO Assisi, Italy 1-3/03/2018.

• Local Organizer of the Spring Meeting of the Oncology Radiotherapy Group (ROG) of the European Organization for Cancer Research and Treatment (EORTC). Florence, Italy 11-13/03/2018.

• Invited speaker. Panel of Experts. 11th European Breast Cancer Conference (EBCC). Multidisciplinary Team in the Real-World session on "Young HER2 Negative Patients with Breast Cancer". Barcelona (Spain). 21-23/03/2018.

• ESTRO Conference 37, selected Oral Communication on: "DCIS treated with breast conservative surgery and radiotherapy: a national multicentre experience". Barcelona (Spain). 20-24/04/2018.

• Invited speaker. meeting “I se ed i ma del trattamento del carcinoma mammario metastatico ER+/HER2-“. Ferrara, 11-12 May 2018.
• Invited Speaker. Brescia Meetings in Radiation Oncology “Immunity, drugs, radiation: from biology to comtemporary clinical oncology”. Brescia, 20-21 September 2018.
• Advisory Board coordinator. Corso ECM “Help Desk in aBC. Share the clinical experience”. Firenze, 5 October 2018.
• Advisory Board. Breast Cancer Expert Meeting. Pisa, 13 November 2018.
• Ivited Speaker. Annual Meeting Swedish Breast Medical Oncologist, Brostonkologisk Forening (BOF). Hesselby Slott, Vallingby, Stockholm (Sweden). 23-25 January 2019.
• Panel of Experts. Breast Surgery Toolbox – Hirslanden Klinik St. Anna Brustzentrum (ESTRO representative). “A consensus and toolbox to improve breast conservation rates and to guide axillary management after preoperative systemic therapy (PST)”. Luzern (Switzerland). 8 February 2019.
• Invited Speaker. Meeting “Focus sulla chirurgia oncologica e ricostruttiva della mammella”. Pisa, 11-12 April 2019.
• Invited Speaker. ESTRO 38 Annual Meeting. SP-0463 Towards less radiotherapy in breast cancer treatment. Milan, 27-30 April 2019.
• Executive Committee and Invited Speaker. XI Edition Biannual Meeting “Attualità in Senologia (AIS)”. Firenze, 6-8 November 2019.
• Invited Speaker. VIII Breast Surgery Workshop. “Ductal carcinoma in situ of the breast”. Aarhus, 21-23 May 2019.
• Panel of Experts. III Skagen meeting. Skagen, 4-6 June 2019.
• Advisory Board. “HR+ 2020, Il carcinoma mammario avanzato in alta risoluzione”. Firenze, 21 June 2019.
• Invited Speaker. 29th Residential Course “Modern Radiotherapy, time issues and new drugs”. Roma, 21-23 October 2019.
• Invited Speaker. XXI Congress of the Brazilian Society of Radiotherapy. Rio de Janeiro (Brasil), 23-27 October 2019.
• Invited Speaker. ESMO Breast Cancer Virtual Meeting. “Is cardiac damage still relevant? And how can be avoided?”. Virtual, 23-24 May 2020.
• Invited Speaker. Biannual Meeting 12th European Breast Cancer Conference (EBCC-12) (virtual). European SocieTy for Radiotherapy & Oncology (ESTRO) - State of the Art in Radiation Oncology 2020. The best treatment in breast cancer radiotherapy 3D vs. IMRT. Virtual, 2-3 October 2020.
• Invited Speaker. Breast Turkish International Meeting Breastambul (hybrid/virtual). Istanbul, virtual, 17-18 October 2020.
• Invited Speaker. ESTRO40 Annual Meeting (virtual). 28 Nov – 1 Dec 2020.
• Invited Speaker. World Congress of Brachytherapy 2020 (virtual). Debate: Partial Breast Irradiation with 1-3 fractions. Virtual, 6-8 May 2021.
• Invited Speaker. Highlights St. Gallen Breast Cancer Conference 2021. Webinar, 28 May 2021.
• Invited Speaker. MORE TIME MORE LIFE. “Advanced Breast Cancer HR+ HER2-, dagli studi alla pratica clinica: gli inibitori CDK4/6 sono davvero tutti uguali?“. Webinar, 2 July 2021.
• Invited Speaker. Senoforum Accademia di Senologia Umberto Veronesi. 15-16 July 2021.
• Invited Speaker. ESTRO41 Annual Meeting. Session: New endpoints for early breast cancer - Less is more? Presentation title: Health-related quality of life - Primary or surrogate endpoint? Madrid, 27-31 August 2021.
• Faculty member and Speaker. ESMO Virtual Preceptorship on Cancer Care in Elderly Patients. Radiotherapy in older patients. 2-3 September 2021.
• Faculty. Focus Group CNAO: Patologie mammarie. Webinar, 21 September 2021.
• Invited Speaker. Webinar ECM FAD "Il meraviglioso mondo dei PARP inibitori: dalla biologia molecolare alla pratica clinica". Webinar, 23 September 2021.
• Faculty member and Invited Speaker. Breastics24h Breast Oncoplastic. Oncoplastic Multidisciplinary Board Meeting. Webinar, 25 September 2021.
• Invited Speaker and Faculty. ESSO Advanced Course on Breast Cancer Surgery. Live Virtual Course, 24 November 2021.
• Panel of Experts. Assisi ATTM. Assisi, 21-23 February 2022.
• Invited Speaker and Faculty. ESTRO APBI multidisciplinary Course. Virtual, 28-30 March 2022.
• Invited Speaker and Session Chair. Omission of radiation therapy. GBCC Annual Meeting. Seoul, Korea, April 2022.
• Invited Speaker, Chair, and selected proffered paper. ESTRO42 Annual Meeting. Copenhagen, 6-10 May 2022.
• Faculty and Invited Speaker.2° Congresso Rete Senologica Toscana. Cortona, 13-14 May 2022.
• Invited Speaker and Faculty. ESMO Preceptorship programme on breast cancer. Live Virtual Course, 14-15 June 2022.
• Panel of Experts. IV Skagen meeting. Skagen, 21-23 June 2022.
• Faculty and Invited Speaker. 13^th European Breast Cancer Conference (EBCC). Barcelona, Spain, 16-18 November 2022.

• Faculty and Invited Speaker. 18^th St. Gallen International Breast Cancer Conference (SGBCC). Vienna, Austria, 15-18 March 2023.

• Invited Speaker. ESTRO 2023 Clinical Pre-meeting palliative care course. Vienna, Austria, 12 May 2023.
• Invited Speaker. ESTRO 2023 Annual Meeting. Vienna, Austria, 12-16 May 2022.

Management, organization and participation in the activities of national and international research groups.

• Co-Chair of the Inter-regional Section Tosco-Umbra of the Italian Association of Radiotherapy Oncology (GTUOR). Biennium 2013-2015.

• Co-Chair of the Breast Cancer Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Biennium 2014-2016.

• Radiation Oncology Group (ROG) and the Breast Cancer Group (BCG) of the European Organization for Cancer Research and Treatment (EORTC). 2014-today.

• Co-Chair of the Breast Working party (BWP) of the ROG of the EORTC. 2013-2018.

• Selected for the program promoted by the European Organization for Cancer Research and Treatment (EORTC): Early Career Investigator (ECI) EORTC Program. 2017-2019.

• European Organization for Research and Treatment of Cancer (EORTC) - Radiation Oncology Group (ROG) -Disease Oriented Groups Junior Representative (jRDR) for Breast Cancer. March 2018-2020.

• Founding Partner and Chair of the National / International Multi-Center Study Group "Clinical Oncology Breast Cancer Group - Group of Clinical Oncology of Breast Cancer" (COBCG). March 2018-today.

• Member the Italian College of Senologists. 2016-2020.

• Member of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). 2006-today.

• Member of the Italian Association of Radiobiology (AIRB).

• Member of European Society for Radiation Oncology (ESTRO) since 2012

• Member of the European Organization for Research and Treatment of Cancer (EORTC) since 2014.

• Writing Committee of Breast Cancer AIRO Italian Guideline. 2017-2018.

• Reviewer Committee of Breast Cancer AIRO Italian Guideline. 2019-2020.

• Reviewer Committee of Breast Cancer Italian Guideline of the Medical Oncology Italian Association (AIOM). 2018-2020.

• Executive Committee of the Biannual Meeting “Attualità in Senologia”. Florence. 2019 and 2021.

• Scientific Committee of SenoNetwork. 2020-2022.

• Scientific Committee of the National Meeting AIRO. 2016-2022.

• Chair of the Breast Cancer Group of AIRO. 2020-2022.

• Board Member of the Radiation Oncology Scientific Council (ROSC) EORTC. 2020-present.

• Member of the ESTRO SAG for Clinical Radiotherapy SAG. ESTRO Meeting 2020 (virtual), ESTRO Meeting 2021 (Madrid), and ESTRO Meeting 2022 (Copenhagen).

• Board member of the ESTRO-ACROP guidelines breast cancer focus group. 2022-present.

• Scientific Committee of Tuscany Region Senologic Network on axillary management. Comitato Scientifico Regionale sul Trattamento dell'Ascella. Rete Senologica Toscana. 2021-2022.

• Faculty member of the College of the European School of Oncology (ESO). 2022-present.

• Task force member of Accelerated Partial Breast Irradiation (APBI) Replacement: An ASTRO Evidence-Based Clinical Practice Guideline. March, 2022.

• Faculty member of 13^th European Breast Cancer Conference (EBCC). Barcelona, Spain, 16-18 November 2022.

• Faculty member of 18^th St. Gallen International Breast Cancer Conference (SGBCC). Vienna, Austria, 15-18 March 2023.

• Faculty member of 13^4h European Breast Cancer Conference (EBCC). Milan, Italy, March 2024.

• ESTRO clinical Board member. 2023 – 2026.

Responsibility and coordination of scientific works and research

• Co-Principal Investigator. APBI-IMRT-Florence (NCT02104895) phase III trial. Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation. Institution: University of Florence, Italy.

• Sub-Investigator. PERTAIN Trial (Hoffmann-La Roche) A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Hormone Receptor-Positive, HER2-positive Metastatic Breast Cancer patients. NCT01491737.

• Sub-Investigator. SAFE HER trial (Hoffmann-La Roche). A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients with Early HER2-Positive Breast Cancer (SafeHer). NCT01566721.

• Sub-Investigator. BELLE3 trial (Novartis). Randomized, double-blind, placebo-controlled, Phase III trial with BKM120 in combination with fulvestrant in postmenopausal patients with HER2-negative hormone receptor positive, locally advanced or metastatic carcinoma treated with aromatase inhibitors and presented progression during or after therapy with a regimen containing an mTOR inhibitor.

• Sub-Investigator. SAFE phase III trial (NCT02236806). Role of ACE Inhibitors and Beta Blockers as Cardiotoxicity Prevention in Breast Cancer Patients Treated With (Neo) Adjuvant Anthracyclines and / or Trastuzumab: a Four Arm, Placebo Control, Randomized Trial. Institution: University of Florence, Italy.

• Sub-Investigator. GIM13 AMBRA (Oncotech Consortium). Longitudinal cohort study on the therapeutic choices of HER2-negative metastatic breast cancer in Italian clinical practice.

• Sub-Investigator. GIM10 CONSENT (IRCCS AOU San Martino-IST). Phase III clinical study comparing the concomitant and sequential administration of CT and AI as adjuvant treatment of postmenopausal patients with hormone-sensitive breast cancer.

• Sub-Investigator. SANDPIPER Trial (Hoffmann-La Roche). SANDPIPER Study: A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy. NCT02340221.

• Sub-Investigator. BONADIUV phase II trial (NCT02616744). A Single - blind, Randomized, Placebo - controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial. Institution: University of Florence, Italy.

• Sub-Investigator. GIM16 FEVEX (Consorzio Oncotech). Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopausal women with hormone receptor positive (HR +) ad human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC) previously treated with non steroidal aromatase inhibitors (NSAI): a multicentre, phase III trial.

• Sub-Investigator. SINODAR ONE trial (Humanitas Research Foundation - Rozzano, Milan). T1-T2 mammary carcinoma: comparison of excision and preservation of axillary lymph nodes in the presence of metastases to the sentinel lymph node.

• Sub-Investigator. PAINTER trial (Medical Oncology of the Fatebenefratelli Hospital) .PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment. NCT02864030.

• Co-Investigator. LUCY Study: Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1 / 2 Mutations. Eudract Code: 2017-001054-34.

• Co-Investigator. Patients With Her2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer (F. Hoffmann-La Roche Ltd). Protocol Number MO39146.

• Co-Investigator. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Atezolizumab In Combination With Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer "(F. Hoffmann -La Roche Ltd). Protocol Number MO39193. Eudract Number 2016-005119-42.

• Co-Investigator. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of atezolizumab (Anti-PD-L1 antibody) In Combination With Paclitaxel compared With Placebo With Paclitaxel For Patients With Previously Untreated Inoperable Locally Advanced Or Metastatic Triple Negative Breast Cancer (F. Hoffmann-La Roche Ltd). Protocol Number MO39196 Eudract Number 2016-004024-29.

• Co-Investigator. Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial Of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone For Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer (Pallas). Alliance Foundation Trials, Llc. Clinicaltrials.Gov Identifier: Nct02513394.

• Co-Investigator. Non-Interventional Study To Characterize The Real World Treatment Patterns And Outcomes Of Women With ER+, HER2- Advanced Or Metastatic Breast Cancer In Italy (Pfizer). Protocol Number A5481031.

• Co-Investigator. Compleement-1: “An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre / postmenopausal women with hormone receptor-positive (HR +) HER2- negative (HER2) advanced breast cancer (BC) with no prior hormone therapy for advanced disease”. Eudract Code: 2016-003467-19.

- Principal Investigator. Phase III trial (EUROPA trial). ExclUsive endocRine therapy Or Partial breast irradiation for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomized phase 3 non-inferiority trial. ClinicalTrial.gov Identifier NCT04134598. Institution: University of Florence.

Scientific responsibility for national and international projects.

• Professional Research Assign at the Department of Clinical Physiopathology of the University of Florence, Italy. Topic: "Risk-assessment in Radiotherapy". European project no. LSHC-CT-2004-503564 - VI Program MAESTRO (Methods and Advanced Equipment for Simulation and Treatment in Radio Oncology). 10/1/2005 - 01/03/2006.

• Research fellowship Topic “Evaluation of genetic predisposition to induced radio toxicity” (DAI Oncology, SODC Radiotherapy) of the Department of Clinical Pathophysiology of the University of Florence, Italy. (2009 Regional Health Research Grant). 01/07/2010 - 30/07/2011.

Participation in editorial committees of magazines and editorial series

• Cancer and Clinical Oncology (ISSN: 1927-4858, Print; ISSN: 1927-4866, Online)

• Case Reports in Pathology (ISSN: 2090-6781)

• Translational Cancer Research (Translator Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803)

• Subject Editor (Radiation Therapy) Critical Review in Oncology/Hematology (ISSN 1040-8428).

Reviewer for Scientific Journals

• Cancer and Clinical Oncology (ISSN: 1927-4858, Print; ISSN: 1927-4866, Online).

• Case report in Pathology (ISSN: 2090-6781).

• BMC Cancer (ISSN: 1471-2407).

• Onkologie (ISSN: 1423-0240).

• Medical radiology (ISSN: 1826-6983).

• Tumor Biology (Tumor Biology Tumor Markers, Tumor Targeting and Translational Cancer Research, ISSN: 1010-4283).

• Clinical Breast Cancer (ISSN: 1526-8209).

• Urologic Oncology (ISSN: 1078-1439).

• The Breast (ISSN: 0960-9776).

• Future Oncology (ISSN 1479-6694).

• Radiotherapy and Oncology (ISSN 0167-8140)

• Critical Review in Oncology/Hematology (ISSN 1040-8428)

Assignments in University teaching courses and research institutes

• Fellowship. Oncology Radiotherapy Unit - Radiation Oncology Unit, Royal Marsden Hospital, London (UK). Supervisor: Prof. Michael Brada from 01.10.2008 to 31.03.2009. Clinical activity at the "Royal Marsden Hospital" (RMH), London (UK) and research activity at The Institute of Cancer Research (ICR), London, Sutton (UK). Consulting at the Chelsea and Sutton institute of the RMH specialized in lung and brain cancer (Prof. Michael Brada). Outpatient clinical activity at the Sutton site of the specialized RMH in hematological malignancies (Prof. Alan Horwich). Discussion and participation in Multi-Diciplinary Team (MDT) of lung cancer (Sutton's RMH site) and cerebral cancer (St. George Hospital, Wimbledon, London).

• Frontal teaching and student tutor in Master's Degree course, Medical School and Three-year Degree Course in Medical Radiology Techniques.

• Frontal teaching and mentoring in specialized training Specialization school in Radiation Oncology AOUC Florence.

• Thesis co-supervisor (Supervisor Prof. Lorenzo Livi) Medical School, University of Florence, Italy.

• Local Speaker of the Advanced Course on Multidisciplinary Breast Cancer Treatment of the European Society of Radiotherapy Oncology (ESTRO), ESTRO Teaching Course on the Multidisciplinary Management of Breast Cancer 2015, ESTRO School of Radiation Oncology.

• Teacher of the ESTRO Teaching Course on Accelerated partial Breast Irradiation. 2020-today.

• Teacher of the ESTRO teaching Course on Breast Cancer. 2024-on.

University of Florence academic teaching courses

Clinical activity

Main clinical care responsibilities (Radiation Oncology Unit - AOU Careggi Firenze, Prof. Lorenzo Livi):

• Clinical, diagnostic, therapeutic and follow-up phases; participation in MDT, concomitant therapies (radiotherapy, chemotherapy, molecular therapies), supportive and palliative therapies;

• Referent Breast Cancer MDT of the AOU Careggi as Clinical Oncologist/ Radiation Oncologist;

• Day-Hospital activities: chemotherapies and molecular therapies in primary, adjuvant and metastatic settings of cancer patients; supportive therapy; management of revaluations under treatment; participation in internal, national and international clinical trials (sponsored and academics);

• Activities in the radiotherapy planning unit: management of early therapy and tolerance consulting; linear accelerators, tomotherapy, GammaKnife, CyberKnife; use of treatment plan systems for the contouring and planning of standard, conformational, stereotactic, IMRT, VMAT (XiO, Odyssey, Pinnacle, Monaco) treatments;

• Knowledge of record and verify systems; use of PACS systems for image management; use of patient positioning verification systems and immobilization systems.

Florence, Italy

07/07/2023